We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Blood and Body Fluid Analyzer Developed for Medium-Sized Labs

By LabMedica International staff writers
Posted on 21 May 2009
Print article
A new, automatic analyzer has been developed for analysis of blood and body fluids in hospitals with medium-sized laboratories. The analyzer will play an important part in the diagnosis of a number of diseases, including different types of infection and leukemia.

Automated digital cell morphology is the process by which cells are automatically located on a stained peripheral blood or body fluid smear, preclassified, stored, and presented for confirmation by a technologist. The images then become available for access by physicians at any time for perusal.

Using the new analyzer laboratories can achieve time reductions (up to 50 %) and more standardized analyses. To count and classify white blood cells is a very common routine analysis in hematology laboratories. Trends indicate that medium-sized laboratories would like to automate the analytical process. Increased automation gives lab personnel more time and increases objectivity, safety, and standardization in the analytical work.

Called CellaVision DM1200, the instrument is CellaVision's (Lund, Sweden) next generation analyzer, and is the latest addition to the company's current range of products that include CellaVision DM96 and CellaVision DM8. The new instrument is based on a new cost-reduced hardware platform, is automated, and has a wider range of uses. Body fluid software can be added to the analyzer for analysis of fluids such as cerebrospinal fluid.

The official product launch will take place at the international Annual Meeting & Clinical Lab Expo AACC in Chicago, USA, on July 20-24, 2009. CellaVision DM1200 will be commercially available in Europe in around the same time.

CellaVision AB develops and markets systems for automatic differentials of white blood cells and erythrocyte morphology, and software for education and quality assurance of differentials.

Related Links:

CellaVision


Gold Member
Fully Automated Cell Density/Viability Analyzer
BioProfile FAST CDV
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Herpes Simplex Virus ELISA
HSV 2 IgG – ELISA
New
FOB+Transferrin+Calprotectin+Lactoferrin Test
CerTest FOB+Transferrin+Calprotectin+Lactoferrin Combo Test

Print article

Channels

Clinical Chemistry

view channel
Image: The GlycoLocate platform uses multi-omics and advanced computational biology algorithms to diagnose early-stage cancers (Photo courtesy of AOA Dx)

AI-Powered Blood Test Accurately Detects Ovarian Cancer

Ovarian cancer ranks as the fifth leading cause of cancer-related deaths in women, largely due to late-stage diagnoses. Although over 90% of women exhibit symptoms in Stage I, only 20% are diagnosed in... Read more

Molecular Diagnostics

view channel
Image: The breakthrough could result in a higher success rate using a simple oral swab test before IVF (Photo courtesy of Shutterstock)

POC Oral Swab Test to Increase Chances of Pregnancy in IVF

Approximately 15% of couples of reproductive age experience involuntary childlessness. A significant reason for this is the growing trend of delaying family planning, a global shift that is expected to... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: The new algorithms can help predict which patients have undiagnosed cancer (Photo courtesy of Adobe Stock)

Advanced Predictive Algorithms Identify Patients Having Undiagnosed Cancer

Two newly developed advanced predictive algorithms leverage a person’s health conditions and basic blood test results to accurately predict the likelihood of having an undiagnosed cancer, including ch... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.